2-仲丁基异氰酸苯酯 | 480439-17-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-仲丁基异氰酸苯酯
• 中文别名: 2-SEC-丁基苯基异氰酸酯
• 英文名称: 2-sec-butylphenyl isocyanate
• 英文别名: 1-sec-butyl-2-isocyanatobenzene；1-butan-2-yl-2-isocyanatobenzene
• CAS: 480439-17-6
• 化学式: C₁₁H₁₃NO
• mdl: MFCD03701588
• 分子量: 175.23
• InChiKey: WJDNRCCJBHKDTR-UHFFFAOYSA-N

物化性质

• 沸点：
  219-220 °C(lit.)
• 密度：
  0.999 g/mL at 25 °C(lit.)
• 闪点：
  195 °F

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 海关编码：
  2929109000

反应信息

• 作为反应物：
  描述：

  2-仲丁基异氰酸苯酯 在 palladium 10% on activated carbon 、 氢气 、 lead(IV) tetraacetate 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 20.0 ℃ 、206.85 kPa 条件下， 反应 0.58h， 生成 4-sec-butyl-1-hydroxy-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  Synthesis and SAR of 1-Hydroxy-1H-benzo[d]imidazol-2(3H)-ones as Inhibitors of d-Amino Acid Oxidase

  摘要：

  A series of 1-hydroxy-1H-benzo[d]imidazol-2(3H)-ones were synthesized and evaluated for their ability to inhibit human and porcine forms of D-amino acid oxidase (DAAO). The inhibitory potency is largely dependent on the size and position of substituents on the benzene ring with IC50 values of the compounds ranging from 70 nM to greater than 100 mu M. Structure-activity relationships of this new class of DAAO inhibitors will be presented in detail along with comparisons to previously published SAR data from other classes of DAAO inhibitors. Two of these compounds were given to mice orally together with D-serine to assess their effects on plasma D-serine pharmacokinetics.

  DOI：

  10.1021/ml300212a
• 作为产物：
  描述：

  光气 、 2-(1-甲丙基)苯胺 在 碳酸氢钠 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 生成 2-仲丁基异氰酸苯酯
  参考文献：
  名称：

  Structural optimization of a CXCR2-directed antagonist that indirectly inhibits γ-secretase and reduces Aβ

  摘要：

  Amyloid beta(A beta), a key molecule in the pathogenesis of Alzheimer's disease (AD), is derived from the amyloid precursor protein (APP) by sequential proteolysis via beta- and gamma-secretases. Because of their role in generation of A beta, these enzymes have emerged as important therapeutic targets for AD. In the case of gamma-secretase, progress has been made towards designing potent inhibitors with suitable pharmacological profiles. Direct gamma-secretase inhibitors are being evaluated in clinical trials and new strategies are being explored to block gamma-secretase activity indirectly as well. In this regard, we have previously reported an indirect regulation of gamma-secretase through antagonism of CXCR2, a G-protein coupled receptor (GPCR). We demonstrated that N-(2-hydroxy-4-nitrophenyl)-N'-(2-bromophenyl)urea (SB225002), a selective inhibitor of CXCR2 also plays a role in an indirect inhibition of gamma-secretase. Furthermore, we reported a similar to 5-fold difference in the selective inhibition of APP versus Notch processing via gamma-secretase following treatment with SB225002. Herein we describe the synthesis and optimization of SB225002. By determination of the structure-activity relationship (SAR), we derived small molecules that inhibit A beta 40 production with IC(50) values in the sub-micromolar range in a cell-based assay and also validated the potential of CXCR2 as a new target for therapeutic intervention in AD. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.09.051

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• Urea Derivative
  申请人：Kurata Hitoshi

  公开号：US20070249620A1

  公开（公告）日：2007-10-25

  The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R 1 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R 3 is a hydrogen atom or others; R 4 and R 5 , which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are I or another number) or others; and A is a group represented by the formula —NH—C(═O)— or others], or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有出色DGAT抑制作用的脲衍生物或其药理学上可接受的盐。其中，该脲衍生物具有以下公式：[式中，R1是C6-C10芳基，可以独立地被来自置换基团a或其他的基团单独到五重取代；R是C6-C10芳基，可以独立地被来自置换基团a或其他的基团单独到五重取代；E是具有公式（II）或公式（III）的基团（其中，R3是氢原子或其他；R4和R5相同或不同，是氢原子或其他；X和U相同或不同，是由公式CH或其他表示的基团；m和n相同或不同，是I或其他数字）或其他；A是由公式—NH—C(═O)—或其他表示的基团]，或其药理学上可接受的盐。
• UREA DERIVATIVE
  申请人：Sankyo Company, Limited

  公开号：EP1764360A1

  公开（公告）日：2007-03-21

  The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R1 is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R2 is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R3 is a hydrogen atom or others; R4 and R5, which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are 1 or another number) or others; and A is a group represented by the formula -NH-C(=O)- or others], or a pharmacologically acceptable salt thereof.

  本发明涉及一种脲衍生物或其药理上可接受的盐，具有极佳的 DGAT 抑制作用。一种脲衍生物具有以下式子： [其中 R1 是 C6-C10 芳基，可独立地被选自取代基 a 或其它的基团一至五取代；R2 是 C6-C10 芳基，可独立地被选自取代基 a 或其它的基团一至五取代；E 是具有式(II)或式(III)的基团（其中 R3 是氢原子或其它；R4和R5相同或不同，为氢原子或其它；X和U相同或不同，为式CH代表的基团或其它；m和n相同或不同，为1或其它数字）或其它；以及A为式-NH-C(=O)-代表的基团或其它]，或其药理学上可接受的盐。
• BENEFIT AGENT DELIVERY COMPOSITIONS
  申请人：The Procter and Gamble Company

  公开号：EP2111443A2

  公开（公告）日：2009-10-28
• Benefit agent delivery compositions
  申请人：Smets Johan

  公开号：US20080200363A1

  公开（公告）日：2008-08-21

  Benefit agent delivery compositions, compositions, packaged products and displays comprising such benefit agent delivery compositions, and processes for making and using such benefit agent delivery compositions, compositions, packaged products and displays. Such compositions have improved deposition and retention properties that may impart improved benefit characteristics to a composition and/or situs.